Repatha Performance Contracting: Sweetening The Pot For Payers
Executive Summary
Amgen suggests it would respond to payer price concerns by pursuing contracts that tie the drug’s net cost (after rebates) to its value in the relatively narrow population it is indicated for. Some payers eye choosing either Repatha or rival Praluent based on price.
You may also be interested in...
Praluent Coverage: Being First May Not Matter As Payers Await Repatha
The pricing advantage that might have been available to Praluent as first-in-class is undercut by the fact that it only has about a month’s lead time over the competition.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.